Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial

Deucravacitinib, a selective, TYK2 inhibitor, in psoriatic arthritis: achievement of minimal disease activity components in a phase 2 trial

<p><strong>Objectives:</strong> Deucravacitinib is a novel, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor belonging to a distinct class of enzyme inhibitors. In a phase 2 trial in psoriatic arthritis (NCT03881059), deucravacitinib was significantly more efficacious...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	Kavanaugh, A, Coates, LC, Mease, PJ, Nowak, M, Hippeli, L, Lehman, T, Banerjee, S, Merola, JF
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	Oxford University Press 2024

Eitemau Tebyg

Deucravacitinib, a TYK2 inhibitor, safety in psoriasis and psoriatic arthritis: What should a dermatologist know?
gan: Inês Pereira Amaral, et al.
Cyhoeddwyd: (2023-06-01)

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial
gan: Strand, V, et al.
Cyhoeddwyd: (2024)

Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
gan: Robert Roskoski, Jr.
Cyhoeddwyd: (2023-03-01)

Psoriatic arthritis
gan: FitzGerald, O, et al.
Cyhoeddwyd: (2021)

Methotrexate in psoriasis and psoriatic arthritis
gan: Coates, L, et al.
Cyhoeddwyd: (2020)

Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far
gan: Ana Martins, et al.
Cyhoeddwyd: (2023-05-01)

Measuring outcomes in psoriatic arthritis
gan: Ogdie, A, et al.
Cyhoeddwyd: (2020)

GRAPPA 2021 treatment recommendations for psoriatic arthritis
gan: Soriano, ER, et al.
Cyhoeddwyd: (2023)

Treatment to target in psoriatic arthritis with apremilast: probability of achieving targets and comprehensive control of disease manifestations
gan: Mease, PJ, et al.
Cyhoeddwyd: (2020)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
gan: Ogdie, A, et al.
Cyhoeddwyd: (2023)

Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study
gan: Coates, LC, et al.
Cyhoeddwyd: (2021)

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
gan: Ian M. Catlett, et al.
Cyhoeddwyd: (2024-09-01)

The benefits and challenges of setting up a longitudinal psoriatic arthritis database
gan: Gladman, DD, et al.
Cyhoeddwyd: (2018)

Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
gan: Coates, LC, et al.
Cyhoeddwyd: (2022)

Considerations for the definition of remission criteria in psoriatic arthritis
gan: Mease, P, et al.
Cyhoeddwyd: (2017)

Safety and efficacy of bimekizumab in patients with psoriatic arthritis: 2-year results from two phase 3 studies
gan: Mease, PJ, et al.
Cyhoeddwyd: (2024)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
gan: Mease, P, et al.
Cyhoeddwyd: (2017)

Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
gan: Helliwell, PS, et al.
Cyhoeddwyd: (2022)

Measurement properties of the minimal disease activity criteria for psoriatic arthritis
gan: Coates, L, et al.
Cyhoeddwyd: (2019)

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis
gan: Coates, L, et al.
Cyhoeddwyd: (2017)

Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
gan: Gossec, L, et al.
Cyhoeddwyd: (2024)

Psoriatic arthritis: prospects for the future
gan: Hackett, S, et al.
Cyhoeddwyd: (2022)

Comparison of different remission and low disease definitions in patients with psoriatic arthritis and evaluation of their prognostic value
gan: Coates, LC, et al.
Cyhoeddwyd: (2018)

Outcome measures in psoriatic arthritis: where next?
gan: Hackett, S, et al.
Cyhoeddwyd: (2022)

S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study
gan: S Banerjee, et al.
Cyhoeddwyd: (2022-10-01)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
gan: Taylor, PC, et al.
Cyhoeddwyd: (2020)

How should we define disease and outcomes in axial psoriatic arthritis?
gan: Coates, LC
Cyhoeddwyd: (2021)

The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study
gan: Petersen, MB, et al.
Cyhoeddwyd: (2023)

In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity
gan: Michaela Prchal-Murphy, et al.
Cyhoeddwyd: (2015-11-01)

Identification of psoriatic arthritis in patients with psoriasis
gan: Coates, LC, et al.
Cyhoeddwyd: (2023)

Classification and outcome measures for psoriatic arthritis
gan: Leung, Y, et al.
Cyhoeddwyd: (2018)

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
gan: Coates, L, et al.
Cyhoeddwyd: (2020)

Prevalence of psoriatic arthritis patients achieving minimal disease activity in real-world studies and randomized clinical trials: systematic review with metaanalysis
gan: Zardin-Moraes, M, et al.
Cyhoeddwyd: (2019)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
gan: Désirée van der Heijde, et al.
Cyhoeddwyd: (2020-02-01)

Psoriatic arthritis in developing and resource-poor countries
gan: Maharaj, AB, et al.
Cyhoeddwyd: (2020)

LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus
gan: Bindu Murthy, et al.
Cyhoeddwyd: (2023-07-01)

Is axial psoriatic arthritis the same as ankylosing spondylitis with psoriasis: a debate
gan: Coates, LC, et al.
Cyhoeddwyd: (2023)

Axial spondyloarthritis and psoriatic arthritis: mostly overlapping or substantially different diseases?
gan: Braun, J, et al.
Cyhoeddwyd: (2023)

Treatment of recalcitrant lupus erythematosus tumidus with deucravacitinib
gan: Arianna Zhang, BS, et al.
Cyhoeddwyd: (2024-03-01)

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
gan: Strand, V, et al.
Cyhoeddwyd: (2022)